Loth, Eva
[Author];
Banaschewski, Tobias
[Author];
Brandeis, Daniel
[Author];
Bölte, Sven
[Author];
Meyer-Lindenberg, Andreas
[Author];
Mößnang, Carolin Ulrike
[Author];
Tost, Heike
[Author]
;
Baumeister, Sarah
[Other]
The EU-AIMS Longitudinal European Autism Project (LEAP)
: design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
The EU-AIMS Longitudinal European Autism Project (LEAP)
:
design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders
Description:
The tremendous clinical and aetiological diversity among individuals with autism spectrum disorder (ASD) has been a major obstacle to the development of new treatments, as many may only be effective in particular subgroups. Precision medicine approaches aim to overcome this challenge by combining pathophysiologically based treatments with stratification biomarkers that predict which treatment may be most beneficial for particular individuals. However, so far, we have no single validated stratification biomarker for ASD. This may be due to the fact that most research studies primarily have focused on the identification of mean case-control differences, rather than within-group variability, and included small samples that were underpowered for stratification approaches. The EU-AIMS Longitudinal European Autism Project (LEAP) is to date the largest multi-centre, multi-disciplinary observational study worldwide that aims to identify and validate stratification biomarkers for ASD.